FLSM
COGT icon

Frazier Life Sciences Management’s Cogent Biosciences COGT Stock Holding History

Frazier Life Sciences Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,734,601
Closed -$12.5M – 49
2025
Q2 		$12.5M Buy
1,734,601
+798,025
+85% +$4.42M 0.5% 36
2025
Q1 		$5.61M Hold
936,576
– – 0.26% 41
2024
Q4 		$7.31M Hold
936,576
– – 0.3% 42
2024
Q3 		$10.1M Hold
936,576
– – 0.41% 38
2024
Q2 		$7.9M Hold
936,576
– – 0.37% 39
2024
Q1 		$6.29M Sell
936,576
-1,058,691
-53% -$6.54M 0.27% 43
2023
Q4 		$11.7M Buy
1,995,267
+493,884
+33% +$3.78M 0.63% 39
2023
Q3 		$14.6M Hold
1,501,383
– – 0.97% 25
2023
Q2 		$17.8M Sell
1,501,383
-657,771
-30% -$7.55M 1.06% 23
2023
Q1 		$23.3M Buy
2,159,154
+50,000
+2% +$640K 1.69% 13
2022
Q4 		$24.4M Buy
2,109,154
+35,000
+2% +$434K 1.52% 18
2022
Q3 		$30.9M Sell
2,074,154
-20,000
-1% -$274K 2.38% 11
2022
Q2 		$18.9M Sell
2,094,154
-557,600
-21% -$3.81M 1.78% 15
2022
Q1 		$19.9M Buy
+2,651,754
New +$18.5M 1.69% 19

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management's COGT Position: Q3 2025 in Review

Frazier Life Sciences Management sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 1,734,601 shares — an estimated $12.5M sold.

Frazier Life Sciences Management first reported a position in COGT in Q1 2022 and held it in 14 quarters. The position peaked at $30.9M in Q3 2022. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

  • Frazier Life Sciences Management reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,734,601 Cogent Biosciences shares in Q3 2025, an estimated $12.5M.
  • Frazier Life Sciences Management first reported a position in Cogent Biosciences in Q1 2022 and held it in 14 quarters.
  • Frazier Life Sciences Management's Cogent Biosciences position peaked at $30.9M in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.